HSPH1 and melanoma: In the first phase of the clinical trial, subjects diagnosed with third- and fourth-stage melanoma were enrolled to assess the efficacy of a vaccine incorporating the chaperone complex comprising human HSP110 and gp100, which had previously demonstrated success in preclinical evaluations (NCT01744171).